Kardigan targets IPO to support cardiology pipeline progression

Pharmaceutical Technology

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.

pharminent May 27, 2026 (Last updated: May 27, 2026)

Pharmaceutical Technology

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.

Related Stories